Benitec Biopharma gets ~$21.1M from Suvretta warrant exercise; shares outstanding rise to 17.9M

Benitec Biopharma Inc.

Suvretta Capital waived 19.99% beneficial ownership limit on warrants; new cap set at 49.9%.
Exercised 588,236 Series 2 warrants at $1.9299, 5,181,347 warrants at $3.86, and 1,368,180 pre-funded warrants at $0.0001.
Issued total 7,137,763 shares to Suvretta funds for aggregate proceeds of ~$21.1 million.
Outstanding common stock increased to 17,893,765 as of Oct 8, 2024, from ~10.6 million prior.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.